INTRODUCTION
Administration of either polyclonal or monoclonal antibodies (MAb) against fat cell membranes reduces body fat content in different species. However, the effectiveness of this technique has been inconsistent in rodents (Dulor et al., 1990; Flint, 1998) , sheep (Nassar and Hu, 1991) , swine (Kestin et al., 1993; Wright and Hausman, 1995; De clercq et al., 1997) , and chickens (Butterwith et al., 1989; Wu et al., 2000a,b) . These variable results are attributed to a lack of tissue specificity of the antibodies. Kestin and coworkers (1993) used in vivo injection of anti-adipocyte antisera to decrease fat content and increase lean content in pigs. Anti-adipocyte polyclonal or MAb also decreased body fat content in rats (Flint et al., 1986; Flint, 1998) , in pigs (Wright and Hausman, 1995; De clercq et al., 1997) , and in chickens (Wu et al., 2000a) . Despite antisera specificity, complement-mediated cytotoxicity is responsible for adipocyte cell lysis, at least in vitro (Flint et al., 1986; Wright and Hausman, 1995; De clercq et al., 1997) , and probably in vivo as 1 To whom correspondence should be addressed: a-cartwright@ tamu.edu. 1640 hatch rate. In Trial 2, adipose tissue (pectoral, femoral, and abdominal), major organ (heart, liver, and spleen), and total body weights at 14 d of age were not affected by in ovo injection. Hatch success rate of eggs was not significantly different among treatments. However, by 6 wk of age, in ovo injection of MAb significantly reduced (P ≤ 0.05) abdominal fat pad weight by more than 28%. This relative fat pad mass reduction occurred without affecting femoral or pectoral fat tissues. Total body weight and feed intake were not affected among treatments. Our experiments demonstrated for the first time that in ovo administration of anti-adipocyte MAb on Day 15 of embryogenesis reduced the chicken abdominal fat pad mass by 42 d of age without affecting growth or body weight.
well. Poor growth or loss of health resulting from efforts to reduce fat development in vivo is attributed to crossreactivity of the antibodies against non-fat cells. Butterwith et al. (1989) failed to reduce body fat content of chickens by using an anti-adipocyte polyclonal antibody. This failure was attributed to a lack of tissue specificity of the polyclonal antibody. Dong et al. (1991) developed polyclonal antibodies to chicken adipocytes and removed cross-reactivity by tissue adsorption. However, more recent application of MAb has yielded more adipose-directed results without detrimental effects on other tissues in pigs (Wright and Hausman, 1995; De clercq et al., 1997) , rats (Flint, 1998) , and chickens (Wu et al., 2000a) .
In ovo administration provides a convenient method to manipulate the internal environment of embryogenesis. In ovo administration of ovine growth hormone increases the body weight, skeletal growth, and feed efficiency of male broilers. These chickens also exhibit larger adipocytes with correspondingly less adipocytes per gram of tissue (Hargis et al., 1989) . Dewil et al. (1998) reported that in ovo administration of vorozole, an aromatase inhibitor, causes masculinization of postnatal hormone levels and reduces the relative abdominal fat Abbreviation Key: MAb = Monoclonal antibody. pad weight, especially in female chickens. The advent of the INOVOJECT 2 machine, which can achieve efficient in ovo administration of vaccines or other compounds (Johnston et al., 1997) , offers an opportunity for use of MAb to alter body fat development in chickens.
Adipose tissue occurs as discrete depots and within other tissue, such as muscle. Chickens have a relatively lower intramuscular fat content compared with other food mammals (e.g., cows, sheep, and pigs). In chickens, adipose depots differ in size and time of development. Compared with pectoral and femoral adipose depots, the abdominal depot has a relatively faster rate of growth in chickens after hatch. In addition, the abdominal depot is almost imperceptible at hatch, whereas pectoral and femoral fat depots are well-developed (Butterwith, 1989) . Therefore, the objective of this study was to determine the effects of in ovo administration of MAb on chicken adipose tissue development.
MATERIALS AND METHODS

Monoclonal Antibodies
Three MAb (designated D2F5, C4E4, and A3E2) developed in this laboratory were chosen for this study because of their specificity of lipid-containing cells (Wu et al., 2000b) . These MAb also reduced adipocyte cluster numbers in vitro (Wu et al., 2000a,b) and fat pad mass in vivo (Wu et al., 2000a) . These MAb more effectively reduced fat cell cluster numbers in vitro as a pool of two or more MAb than when administered singly (Wu et al., 2000a) . Therefore, a pool of three MAb was used in this study. All three MAb are IgG1 subclass with κ light chain (Wu et al., 2000b) .
Intravenous Injection of Monoclonal Antibody Mixtures into Chicken Embryos
Monoclonal antibodies were injected directly into the allantoic blood vessels of the embryo. Several large and stable veins close to the membrane of the egg were located by candling 15-d-old embryos. A Dremel tool fitted with dental drill bits was used to circumscribe a 1-cm 2 portal through the shell. This shell section was removed carefully without damaging the inner membrane. A small volume (approximately 50 µL) of solution as described later, was injected under a sterile hood. The shell portal was sealed with tissue-embedding medium after treatment. The injected eggs were returned to the incubator until they hatched. volume of saline solution. Chickens were identified by wing bands and housed separately by treatment in brooder chicken batteries after hatch. The hatch success rate of each treatment was recorded. Feed and water were supplied ad libitum. Feed intake and body weight were measured two times per week. At 42 d of age, chickens were killed by cervical dislocation. The abdominal fat depot was removed and weighed.
Trial 2. One-hundred and eighty 15-d broiler chicken eggs (Ross × Ross) were randomly assigned to three groups: non-injected, MAb-injected, and control mouse IgG-injected (four replicates per treatment; 15 eggs per replicate). Control IgG-injected and MAb-injected eggs were intravenously injected with either 0.2 mg MAb mixture (three MAb designated D2F5, C4E4, and A3E2; protein ratio 1:1:1) or a control nonreactive mouse IgG, respectively. Noninjected eggs served as the negative control. At hatch, sex was determined by feather development, and chicks were divided into sex, treatment, and replicate subclasses before placement into brooder chicken batteries after hatch. Hatch success rate of each treatment was recorded.
Feed and water were supplied ad libitum. Feed intake and body weight were measured three times per week for the first 2 wk and two times per week for the remainder of the study. At 14 d of age, one chicken of each replicate was killed by cervical dislocation. Major organs (heart, liver, and spleen) and fat depots (subcutaneous pectoral, femoral, and abdominal) were removed and weighed. At 42 d of age, chickens were killed by cervical dislocation, and the abdominal fat depot and liver were removed and weighed. Samples of adipose tissues were fixed and stored for future analysis.
Statistical Analysis
Adipose tissue and major organ weights were expressed as percentages of total body weight of the individual chicken. Data were subjected to analysis of variance using the GLM procedure of SAS (SAS Institute Inc., 1985) . Differences among treatment means of this study were determined by least square contrast by using the PDIFF option of SAS. Validity of statistical difference of percentage data was confirmed by arcsin conversion.
RESULTS AND DISCUSSION
The MAb used in this study are specific for lipid droplet-containing cells (Wu et al., 2000b) . These antibodies, in the presence of complement, effectively reduce adipocyte cluster numbers in vitro (Wu et al., 2000a,b) and pectoral adipose pad mass in vivo (Wu et al., 2000a) . In Trial 1, injection of MAb mixtures at 15 d of embryonic development ultimately reduced the relative abdominal fat pad mass in 6-wk-old layer chickens in a dose-dependent manner (Figure 1) . A dose-related response caused approximately a 30 to 40% reduction in abdominal fat pad mass compared with the response of noninjected embryos. Higher doses of MAb injection reduced (P ≤ 0.05) the abdominal fat pad mass in males and females, whereas the 0.05-mg dose was ineffective, and the 0.1-mg dose was effective only in males (Table 1 ). The results suggest that male chickens were more sensitive than female chickens. Male and female chickens have different growth patterns and nutritional requirements. Males grow faster than female chickens, deposit less fat proportionally, and have a higher slaughter yield. However, a treatment-by-sex interaction was not detected. The doseresponse curves of male (P ≤ 0.01) and female (P ≤ 0.02) data each defined significant lines (Figure 1 ). These lines were not different from one another. Therefore, the illustrated line represents combined data.
Body weight and feed intake were not affected by in ovo MAb injection during the study (data not shown). Hatch success rates of eggs injected with 0, 0.05, 0.1, and 0.2 mg MAb were not different (Table 1 ). All hatched Different superscripts indicate that the treatment value is significantly different (P < 0.05) from the control value (0 mg MAb) within a sex. Fifteen-day-old chicken embryos were injected in ovo with a mixture of three MAb in saline solution or saline alone via the allantoic circulation. Injected eggs were resealed with tissue-embedding media and incubated to hatch.
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Ratio indicates the number of successful hatches to total number of injected eggs, respectively.
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The number of birds in each treatment-sex subclass is indicated. 4 Abdominal fat pad mass was expressed as a percentage of body weight. chickens survived and thrived without observable effects on health. However, only two of 12 fertilized eggs hatched in the 0.4-mg treatment group. Embryo examination indicated that death occurred at the late embryonic stage (Day 16 to 18 of embryogenesis). A similar effect was noted after in vivo administration of 0.4 mg MAb to newly hatched chicks (Wu et al., 2000a) . The basis of these deaths is unknown, but is speculated to be due to endotoxin contamination of the MAb preparation.
Small numbers of chickens were used in this study because of the limited amounts of MAb that were available for injection. Although MAb injection reduced abdominal fat pad mass, total body weight was not affected. Kestin et al. (1993) , using pigs, and Flint et al. (1986) , using rats, reported that the use of polyclonal antibodies against fat tissues decreased fat tissue mass and increased percentage of lean tissue. These studies suggest that the use of larger numbers of treated chickens might also reveal increases in percentage of lean tissues.
In Trial 2, in ovo injection of broiler chicken eggs with a pool of three MAb did not affect the pectoral, femoral, or abdominal fat pad weights by 2 wk of age (Table 2) . Hatch success rate of eggs was not significantly different among treatments. Total body weight and major organ weights (heart, liver, and spleen) were also not affected among treatments. However, by 6 wk of age, in ovo injection of MAb reduced (P ≤ 0.05) abdominal fat pad weight by more than 28% (Table 3) . Abdominal fat pad mass reduction occurred without an effect on femoral or pectoral fat tissues (Table 3 ). The MAb injection did not affect total body weight (Table 4) or feed intake (data not shown). However, a treatment-by-sex interaction (P ≤ 0.05) and a sex effect were detected in liver weight (Table 4 ). The heavier livers were expected in the larger body-size males. The sex-treatment interaction is probably an artifact, because the noninjected male liver weighed less than the MAb-injected male liver. However, this difference was not seen when control-injected comparisons were made. These data were considered spurious, because the noninjected male liver was significantly smaller than the female liver when expressed as a percentage of body weight, which is not normally observed. Kestin et al. (1993) reported that local injection of MAb reduced subcutaneous fat in pigs by approximately 30% and increased lean tissue by approximately 20%. Injections in our study reduced abdominal fat percentage by approximately the same proportions. Administration of MAb against chicken adipocyte plasma membranes reduced adipose tissue mass in chickens. The reduction of fat pad mass could be caused by reduction or inhibition of cell number, cell size, or both; neither were measured. Means that share a common superscript are significantly different (P ≤ 0.05).
a−e Means that share a common superscript are significantly different (P ≤ 0.05).
x−y Means that share a common superscript are significantly different (P ≤ 0.05). Fifteen-day-old chicken embryos were intravenously injected in ovo with MAb or mouse IgG (control-injected) or were noninjected.
The mechanism of reduction of adipose tissue caused by in ovo MAb injection was not determined. The unexpected discovery of a toxic effect of a high dosage of MAb (0.4 mg) could be due to an endotoxin contaminant of concentrated MAb. Identification of the adipocyte cell surface antigens bound by the MAbs could contribute to understanding the mechanism that inhibits the growth of chicken adipocytes and the toxic response to the high dose of MAb. Identification of these antigens might also contribute to understanding the control of adipocyte differentiation and body composition. Chicken adipose tissue development was inhibited by exposure to MAb against chicken adipocyte plasma membranes.
